{
    "symbol": "MRSN",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-28 10:50:23",
    "content": " These statements may include, but are not limited to, those related to the therapeutic potential of our product candidates and the potential of our platforms, business strategy, clinical trial designs, initiation, execution and data releases, regulatory plans and objectives, commercial opportunities, collaborations and potential associated payments, operating expenses and cash runway. Now let's turn to UP-NEXT, our ongoing Phase 3 trial of UpRi as a monotherapy maintenance treatment and recurrent platinum-sensitive ovarian cancer that is enrolling patients with NaPi2b positive tumors. Your line is open. Your line is open. Your line is open. Your line is open. We utilize the same DolaLock payload that we've clinically demonstrated and utilized within UpRi, where in that instance, we've been able to characterize a differentiated safety profile with - a lack of peripheral neuro-peripheral neuropathy, neutropenia as well as ocular toxicity whereby the Seattle Genetics platform, my understanding is that it's all patented as well as if it does have limitations associated with peripheral neuropathy and neutropenia ."
}